TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Arrow is the marketing partner in US
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
With the acquisition of these further shares, TWPL has now become company's subsidiary.
The study was conducted in patients with mild to moderate COVID-19
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
Subscribe To Our Newsletter & Stay Updated
